Susceptibility of Candida albicans biofilms grown in a constant depth film fermentor to chlorhexidine, fluconazole and miconazole:: a longitudinal study

被引:85
作者
Lamfon, H
Porter, SR
McCullough, M
Pratten, J
机构
[1] UCL, Eastman Dent Inst, Div Infect & Immun, London WC1X 8LD, England
[2] Univ Melbourne, Fac Med Dent & Hlth Sci, Sch Dent Sci, Melbourne, Vic, Australia
关键词
in vitro; antifungal; antimicrobial; MIC;
D O I
10.1093/jac/dkh071
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
Objectives: The aim of this study was to assess the resistance of Candida albicans biofilms to both antifungal and antimicrobial agents in vitro. Methods: Biofilms of C. albicans were grown on denture acrylic discs in a constant depth film fermentor and maintained with artificial saliva. The MIC of fluconazole, miconazole and chlorhexidine for C. albicans was first determined. Using these data, 72 h biofilms were exposed to these agents at different MIC levels. In order to assess growth, biofilms were removed from the fermentor, incubated in the test agent for various periods, the biofilms disrupted and the viable yeast cells present determined. The MIC for these cells was then also determined. In a separate experiment, biofilms of various ages (2-72 h) were exposed to sub-biofilm MIC concentrations for two different periods. Results: C. albicans biofilms were found to be highly resistant to fluconazole and miconazole compared with the same cells grown in suspension (greater than or equal to1024 x MIC). In contrast, chlorhexidine inhibited the growth of C. albicans biofilms at a concentration up to 8 x MIC. When the susceptibility of biofilms over time was investigated, higher reductions were observed for chlorhexidine and miconazole than fluconazole for biofilms of 2 and 6 h. Conclusions: We have shown in this study that the susceptibility of C. albicans to antifungal and antimicrobial agents changes throughout biofilm development.
引用
收藏
页码:383 / 385
页数:3
相关论文
共 10 条
[1]
Molecular characterization of Candida spp. isolated from the oral cavities of patients from diverse clinical settings [J].
Al-Karaawi, ZM ;
Manfredi, M ;
Waugh, ACW ;
McCullough, MJ ;
Jorge, J ;
Scully, C ;
Porter, SR .
ORAL MICROBIOLOGY AND IMMUNOLOGY, 2002, 17 (01) :44-49
[2]
Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents [J].
Baillie, GS ;
Douglas, LJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (03) :397-403
[3]
Biofilm formation by the fungal pathogen Candida albicans:: Development, architecture, and drug resistance [J].
Chandra, J ;
Kuhn, DM ;
Mukherjee, PK ;
Hoyer, LL ;
McCormick, T ;
Ghannoum, MA .
JOURNAL OF BACTERIOLOGY, 2001, 183 (18) :5385-5394
[4]
Biofilms: Survival mechanisms of clinically relevant microorganisms [J].
Donlan, RM ;
Costerton, JW .
CLINICAL MICROBIOLOGY REVIEWS, 2002, 15 (02) :167-+
[5]
Gilbert P, 1997, Adv Dent Res, V11, P160
[6]
Mechanism of fluconazole resistance in Candida albicans biofilms:: Phase-specific role of efflux pumps and membrane sterols [J].
Mukherjee, PK ;
Chandra, J ;
Kuhn, DA ;
Ghannoum, MA .
INFECTION AND IMMUNITY, 2003, 71 (08) :4333-4340
[7]
*NAT COMM LAB STAN, 1997, M27A NCCLS
[8]
Response of single species biofilms and microcosm dental plaques to pulsing with chlorhexidine [J].
Pratten, J ;
Smith, AW ;
Wilson, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) :453-459
[9]
In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies [J].
Ramage, G ;
VandeWalle, K ;
Bachmann, SP ;
Wickes, BL ;
López-Ribot, JL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3634-3636
[10]
Wilson Michael, 2001, Science Progress, V84, P235, DOI 10.3184/003685001783238998